Cellevolve Bio, a development and commercialization company focused on cell therapies, announced its launch following the successful close of a $6 million seed financing and an exclusive manufacturing partnership with National Resilience.
“Cell therapies are transforming health outcomes for people living with grievous illnesses,” said Derrell Porter, founder and CEO of Cellevolve. “There is an abundance of promising new cell therapy innovations being developed around the world, with early data to support clinical efficacy. Our goal at Cellevolve is to build one of the largest cell therapy pipelines in the industry through partnerships with innovators and deliver that breakthrough science to patients as commercially available therapies.”
The seed financing included the participation of Resilience, Chris Jeffers of Hibiscus BioVentures, and Marcus Whitney of Jumpstart Nova. Whitney and Jeffers will join Cellevolve’s board of directors, and Resilience will appoint a board observer.
Cellevolve named Resilience as its exclusive manufacturing partner. The companies have established a collaboration where Resilience will participate in asset selection and may elect to contribute manufacturing services in exchange for equity in future financings.
“Manufacturing has been a critical barrier holding back cell therapies from reaching patients,” said Rahul Singhvi, CEO of Resilience. “By working with Cellevolve to create new manufacturing processes, we aim to help them produce medicines that can be made quickly and at scale to meet the high demand from people in need.”
Photo: Derrell Porter, founder and CEO of Cellevolve
Author: Rare Daily Staff
Stay Connected
Sign up for updates straight to your inbox.